146 related articles for article (PubMed ID: 15212705)
1. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.
McLeod HL; King CR; Marsh S
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S43-7. PubMed ID: 15212705
[TBL] [Abstract][Full Text] [Related]
2. Current approaches to first-line treatment of advanced colorectal cancer.
Goldberg RM
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
[TBL] [Abstract][Full Text] [Related]
4. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
5. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
6. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
[TBL] [Abstract][Full Text] [Related]
7. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
9. [New oxaliplatin-based regimens].
Zaniboni A
Tumori; 2000; 86(3 Suppl):S25. PubMed ID: 10969612
[No Abstract] [Full Text] [Related]
10. Adjuvant therapy for stage II and III colorectal cancer.
de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-induced dysarthria.
Baz DV; Bofill JS; Nogueira JA
J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
[No Abstract] [Full Text] [Related]
12. Current and ongoing trials with irinotecan in the United States.
Fuchs CS
Semin Oncol; 2003 Aug; 30(4 Suppl 12):9-17. PubMed ID: 14508722
[No Abstract] [Full Text] [Related]
13. [Standard chemotherapy for colonic neoplasms].
Hyodo I
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
[No Abstract] [Full Text] [Related]
14. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Comella P; Lorusso V; Maiorino L; Casaretti R; Cannone M; Massidda B; Putzu C; Leo S; Roselli M; Mancarella S; Palmeri S; Greco E; Vessia G; Sandomenico C; Franco L
Cancer Chemother Pharmacol; 2009 Oct; 64(5):893-9. PubMed ID: 19189106
[TBL] [Abstract][Full Text] [Related]
15. Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Armand JP; Cunningham D; van Cutsem E; Misset JL; Kohne CH
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S5-12. PubMed ID: 10630362
[TBL] [Abstract][Full Text] [Related]
16. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
18. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
[TBL] [Abstract][Full Text] [Related]
19. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM
J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194
[TBL] [Abstract][Full Text] [Related]
20. The impact of pharmacogenomics on gastrointestinal cancer therapy.
Seufferlein T; Boehm BO
Pharmacogenomics; 2002 Sep; 3(5):625-33. PubMed ID: 12223048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
